PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.

Authors

Maria Vidal

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Maria Vidal , Lorena De La Pena , Mafalda Oliveira , Javier Cortes , Antonio Llombart , Aleix Prat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS665)

DOI

10.1200/jco.2013.31.15_suppl.tps665

Abstract #

TPS665

Poster Bd #

17A

Abstract Disclosures

FEATURED

PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.

Authors

Maria Vidal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

Poster

Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.

Poster

NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).

Poster

Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.